



Disclaimer



These slides and any related presentation by management of Comera Life Sciences ("Comera") (collectively, the "presentation") are intended to be provided only to accredited institutional investors who are considering an investment in Comera Life Sciences, and for no other purpose. The information provided in the presentation is intended to highlight certain matters bearing upon the current status of Comera Life Sciences that may be of interest to potential investors. The information provided is not complete, comprehensive or exhaustive, and any potential investor wishing to obtain additional information about topics referenced in the presentation, or other matters in connection with a potential investment, is encouraged to contact Comera Life Sciences.

These slides are intended for limited circulation, and the information provided in the presentation is provided on a confidential basis. Potential investors acknowledge and agree that they will hold the information and all related documents and disclosures in the strictest confidence. The presentation is not intended for public use or distribution, and dissemination, publication, distribution, disclosure, copying or use of the information or disclosures provided in the presentation is expressly prohibited.

The presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be deemed to be any offer solicitation or sale of securities in any state or country in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or country.

Forward-Looking Statements

This presentation contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed business combination between OTR and Comera, including statements regarding the benefits of the transaction, the anticipated timing of the transaction, the products offered by Comera and the markets in which it operates, and Comera's projected future results. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including, but not limited to: (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of OTR's securities, (ii) the risk that the transaction may not be completed by OTR's business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by OTR, (iii) the failure to satisfy the conditions to the consummation of the transaction, including the adoption of the business combination agreement by the stockholders of OTR, the satisfaction of the minimum trust account amount following redemptions by OTR's public stockholders, (iv) the lack of a third party valuation in determining whether or not to pursue the proposed business combination, (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement, (vi) the effect of the announcement or pendency of the transaction on Comera's business relationships, performance, and business generally, (vii) risks that the proposed business combination disrupts current plans of Comera and potential difficulties in Comera's employee

Disclaimer (Continued)



retention as a result of the proposed business combination, (viii) the outcome of any legal proceedings that may be instituted against Holdco, Comera or OTR related to the business combination agreement or the proposed business combination, (ix) the ability to maintain the listing of OTR's securities on the Nasdaq, (x) the price of Holdco's securities may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which Comera operates, variations in performance across competitors, changes in laws and regulations affecting Comera's business and changes in the combined capital structure, (xi) the ability to implement business plans, forecasts, and other expectations after the completion of the proposed business combination, and identify and realize additional opportunities, (xii) the risk of downturns and the possibility of rapid change in the highly competitive industry in which Comera operates, (xiii) the risk that Comera and its current and future collaborators are unable to successfully develop and commercialize Comera's products or services, or experience significant delays in doing so, (xiv) the risk that Comera may never achieve or sustain profitability; (xv) the risk that Comera will need to raise additional capital to execute its business plan, which many not be available on acceptable terms or at all; (xvi) the risk that the post-combination company experiences difficulties in managing its growth and expanding operations, (xvii) the risk that third-parties suppliers and manufacturers are not able to fully and timely meet their obligations, (xviii) the risk of product liability or regulatory lawsuits or proceedings relating to Comera's products and services, and (xix) the risk that Comera is unable to secure or protect its intellectual property and (xx) the risk that the post-combination company's securities will not be approved for listing on Nasdaq or if approved, maintain the listing. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of OTR's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Holdco's registration statement on Form S-4 and the proxy statement/prospectus discussed above and other documents filed by Holdco or OTR from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Holdco, Comera and OTR assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither Holdco, Comera nor OTR gives any assurance that either Comera or OTR will achieve its expectations.

Disclaimer (Continued)



Important Information About the Proposed Business Combination and Where to Find It

In connection with the proposed business combination, Holdco intends to file a registration statement on Form S-4 (initially on a confidential basis) that will include a proxy statement of OTR and a prospectus of Holdco. The proxy statement/prospectus will be sent to all OTR and Comera stockholders. Holdco also will file other documents regarding the proposed business combination with the SEC. Before making any voting decision, investors and securities holders of OTR and Comera are urged to read the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed business combination as they become available because they will contain important information about the proposed business combination and the parties to the proposed business combination.

Investors and securities holders will be able to obtain free copies of the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Holdco through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by OTR may be obtained free of charge from OTR's website at <https://www.otracquisition.com/> or by written request to OTR Acquisition Corp., 1395 Brickell Avenue, Suite 800, Miami, Florida 33131.

Participants in the Solicitation

Holdco, OTR and Comera and their respective directors and officers may be deemed to be participants in the solicitation of proxies from OTR's stockholders in connection with the proposed business combination. Information about OTR's directors and executive officers and their ownership of OTR's securities is set forth in OTR's filings with the SEC, including OTR's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, which was filed with the SEC on March 3, 2021 as amended on December 13, 2021. To the extent that holdings of OTR's securities have changed since the amounts printed in OTR's Annual Report, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed business combination may be obtained by reading the proxy statement/prospectus regarding the proposed business combination when it becomes available. You may obtain free copies of these documents as described in the preceding paragraph.

Overview of OTR Acquisition Corp.



OTR's team has significant public company experience to support Comera's growth plans

100+ years
combined
investing &
operating
experience

Growth
oriented
investors &
operators

Robust M&A
and capital
markets
experience

Long-term
track record
of value
creation
across
sectors

Life sciences
experience



Nicholas J. Singer
Chairman & CEO

- 20+ years of experience in finance and investments
- Co-Founder of two hedge funds that managed each in excess of a billion dollars
- Founder & Executive Chairman of United Parks
- Executive Chairman of IntegriCo Composites
- Chairman of Only What You Need (OWYN)
- Former Board Member of Brooklyn ImmunoTherapeutics (Nasdaq: BTX)



Douglas Anderson
CFO & Director



David Neithardt
Director



Comera Life Sciences Investment Highlights



Proprietary Excipient Technology Platform	<ul style="list-style-type: none"> Proprietary SQore excipient platform technology to develop subcutaneous biologics for improved patient outcomes Lead caffeine-based patented excipient validated in peer-reviewed study and initial <i>in vivo</i> safety studies provide evidence of tolerability
Significant Opportunity	<ul style="list-style-type: none"> Most biologics delivered intravenously despite significant limitations for patients and healthcare system \$220B addressable market in 2020 and expected to grow to \$422B in 2025
Multiple Pharmaceutical Partnerships	<ul style="list-style-type: none"> Agreements with top-tier pharma collaborators for high-value, late-stage/marketed, licensed products with significant licensing, milestone payment and royalty potential Additional partnerships expected
Proprietary Product Pipeline	<ul style="list-style-type: none"> Proprietary pipeline of biologics in development targeting substantial markets and high unmet needs First IND filing expected in Q1 2024
Expertise and Intellectual Property	<ul style="list-style-type: none"> Team with successful track record of drug development and life sciences operating experience Extensive IP protection
Compelling Valuation and Attractive Entry Point	<ul style="list-style-type: none"> Proprietary platform enables potential for significant value creation As Comera continues to execute on its business plan, it should trade in line with more developed biologics companies that tend to trade at higher valuations

Experienced and Accomplished Management Team



James Sherblom
Executive Chairman



Jeffrey S. Hackman
Chief Executive Officer



Neal I. Muni, MD, MSPH
Chief Operating Officer



Robert Mahoney, Ph.D.
Chief Scientific Officer



Successful track record of drug development and life sciences operating expertise

7

Board of Directors: Top-Tier Pharma Expertise



James Sherblom
Executive Chairman

- A founder of Mass Bio Council
- Former SVP & CFO, Genzyme; led first IPO
- Former Chairman and CEO, Transgenic Sciences
- Founding & Managing Partner, Seaflower Ventures
- Activist Social Impact Investor
- Vice Chair, GrainPro Inc.



Jeff Hackman
President/CEO

- 30 years experience in Pharma and Biotech
- Former CEO Novellon
- Head of U.S. Internal Medicine & Oncology for Shire.
- Region head for North America at Baxalta.
- Commercial VP roles at Sigma Tau, Intercell, Emergent BioSolutions and MedImmune



Roopom Banerjee, PhD

- Managing Partner of WhiteLeaf Advisors, Strategic Advisor of Bain Capital and Operating Operator of CRG LP
- Chief Strategy and BD Officer for Agendia
- Board Member of SAGA Diagnostics AB
- Former President and CEO of RainDance Technologies



Barbara Finck, MD

- Board-certified rheumatologist
- 25+ years of preclinical & clinical drug development
- Acting CMO of Coherus
- VP Clinical development at Alza, Eos, PDL & Immunex
- CMO at Osprey Pharmaceuticals and NK Therapeutics



Kirsten Flowers

- 15 years Pharma and Biotech
- Currently CCO for Kura Oncology
- Previously SVP of Commercial Operations at Array Biopharma
- Before Array Kirsten held several leadership positions with Pfizer



Stuart Randle

- 30 years experience in Pharma and Biotech
- Division President of Baxter Healthcare
- CEO of ACT Medical
- President and CEO of GI Dynamics
- Most recently President and CEO of Ivenix
- Board Member of Teleflex and Bescon Roofing Supply



Edward Sullivan

- 35 years experience in Pharma and Biotech advising companies from early-stage IPO to multi-billion-dollar companies
- Trusted counselor to multinational corporations helping them through years of growth and transformational change



John Yee, MD

- Board-certified rheumatologist
- 20+ years academia & Industry
- CMO of Sobi North America
- Medical lead at Genzyme, Flexion, Vertex, Intarcia, AstaZeneca
- Boston Children's Hospital & Harvard Medical School



William Wexler
OTR BOD Rep.

- 30 years experience in finance, operations, general corporate restructuring and, most recently, energy and power generation
- Homer City Holdings: Chairman & CEO
- Upstate New York Power Producers: former Chairman and CEO
- VMR Electronics: former Chief Restructuring Officer



Leading a compassionate new era in medicine.

True medical advances don't spring from technology, experience, or even genius. They're inspired by compassion.

We apply a deep knowledge of formulation science and technology to transform essential biologic medicine from IV to subcutaneous ("SQ") forms, providing patients and families with the freedom of self injectable care to fully realize the potential of these life-changing therapies – and the vast potential of their own lives.



Biologics Market is Massive and Growing Rapidly



Global biologics market was ~\$286B in 2020 and expected to grow to ~\$422B in 2025¹

7 of the top 10 global medicines are biologics²

Products across all major therapeutic indications

Biologics are at the vanguard of cutting-edge biomedical technology and are driving the next generation of treatments for patients

Multiple \$Billion Products

1. Source: <https://www.bccresearch.com/market-research/biotechnology/biologic-therapeutic-drugs-technologies-markets-report.html>; Based on revenues generated by each product as disclosed in the annual reports for such companies that produce each of these products.
 2. Source: <https://www.globenewswire.com/news-release/2018/01/11/1690388/0/en/Global-Biologics-Outsourcing-Market-2018-2027-In-2017-7-out-of-10-Blockbuster-Drugs-were-Biologics-Outnumbering-Small-Molecule-Drugs.html>

Most Biologics Administered Intravenously, with Significant Limitations



Patients

- Pain and discomfort associated with IV access
- Time-consuming (1-4 hours)
- Risk of infection
- Reduced compliance
- Inconvenience – travel, time
- Cannot be self-administered

Healthcare System

- Requires space and time in office
- Requires storage ± refrigeration, supplies
- Requires nursing time
- Increased costs



11



Subcutaneous Administration has Multiple Potential Benefits

Patients

- Less pain and discomfort (smaller needle than IV)
- Less time-consuming
- Less risk of infection
- At-home self-administration
- Higher patient satisfaction
- Improved compliance
- Improved quality of life

Healthcare System

- No need for IV access resources and nursing time
- Reduced costs – supplies, storage, staffing



SQ Dosing Strongly Preferred Over IV by Physicians



Comera conducted market study with over 50 physicians to assess unmet need


Over 70% expressed interest in a SQ version of an IV biologic if available

A clear majority agreed that patient inconvenience was a significant issue with IV

"Traveling and infusion time can sometimes take up half a day for some of my patients. If there were an option to take [the treatment] at home, many of them would be very interested."

- Gastroenterologist in Midwest U.S.


Top issues creating lack of physician satisfaction with IV biologic dosage forms



Source: Ipsos market study and Comera physician interviews, December 2021; base: Total HCPs; n=50 + 5 IDIs with high-prescribing physicians



Increased Viscosity Significant Hurdle to Formulating Most Biologics for SQ Administration



Increased protein concentration needed for smaller dosing volumes leads to increased viscosity

This increased viscosity prevents SQ administration





Excipients Typically Used to Reduce Viscosity, but Lack of Innovation has Plagued Industry

Despite decades of research, a lack of effective excipients remains

Suboptimal excipients can:

Fail to reduce viscosity sufficiently

Destabilize the biologic protein

Increase injection pain

Cause other side effects

Lack of innovation highlighted by FDA Novel Excipient Review Pilot Program
First proposals accepted December 2021

Novel Excipient Review Pilot Program

The Center for Drug Evaluation and Research (CDER) has launched the voluntary Novel Excipient Review Pilot Program (Pilot Program), which is intended to allow excipient manufacturers to obtain FDA review of certain novel excipients prior to their use in drug formulations. This Pilot Program will foster development of excipients that may be useful in scenarios in which excipient manufacturers and drug developers have cited difficulty in using existing excipients.

Excipients are substances added to a therapeutic agent in a drug formulation to aid in manufacturing, delivery, stability and/or patient acceptability



Proprietary Excipient Technology Platform



SQore™ : Validated by Scientific Peer-Review



Value of concept and strength of science confirmed by recent publication in industry-leading Journal of Pharmaceutical Sciences

- Use of caffeine-based excipient to reduce viscosity demonstrated for two mAbs, ipilimumab (Yervoy) and infliximab (Remicade)
 - Ipilimumab: caffeine reduced viscosity from 45-78% in three buffers
 - Infliximab: caffeine reduced viscosity by 77% vs. control
- Caffeine-containing formulations met target stability requirements for a viable drug product
- No loss of biologic activity for either molecule in the presence of caffeine, confirmed by rigorous analytical demonstration




Conclusion: Caffeine-based excipient proven in externally validated, rigorous scientific evaluation to achieve all desired target parameters for a viable SQ formulation


Source: "Caffeine as a viscosity reducer for highly concentrated monoclonal antibody solutions", *Journal of Pharmaceutical Sciences*, 110 (2021) 3594–3604, <https://doi.org/10.1016/j.xpps.2021.06.030>

17

Caffeine-based Excipient is Optimized Viscosity-Lowering Beneficial **SO_{core}** Excipient for Several Biologics



Infiximab formulated in a 20 mM phosphate-acetate buffer at pH 6.0 (control) and in the presence of 75 mM caffeine, 100 mM ArgHCl, or 100 mM NaCl



Ipilimumab formulated in Yervoy commercial formulation vehicle (Comm.) and PBS with or without 75 mM caffeine

Source: "Caffeine as a viscosity reducer for highly concentrated monoclonal antibody solutions" Journal of Pharmaceutical Sciences 110 (2021) 3594–3604 <https://doi.org/10.1015/j.xphs.2021.06.030>



SQ_{ore}™ *in vivo* Data Supports Safety of Caffeine



Pre-clinical proof of concept studies further validate use of SQ_{ore} in SQ drug development

- Animal studies conducted by the Company to assess SQ_{ore}™ formulation viability to deliver mAbs subcutaneously
- Study #1: no toxicity from caffeine formulation on the test animals (Sprague Dawley® rats), upon SQ and IV administration
- Study #2: initiated December 2021, final results expected February 2022; no evidence of local or systemic toxicity reported to-date after test formulation administered to study animals

Study #2 Goals


(started 12/2021,
completion 2/2022)

- Comparison of IV and SQ-administered formulations
- Determine PK profile and bioavailability of mAb formulations upon different routes of administration
- Testing a control formulation vs. a caffeine containing mAb formulation
- Observe the animals (SD rats) for any signs of health effects

Based on data collected-to-date, administered subcutaneously, caffeine-containing mAb formulations have not demonstrated evidence of local or systemic toxicity

19

Dual Pillars of Growth: Partnerships and Proprietary Pipeline Development



SQore™ Platform Leading to Revenue-Generating, High-Value Partnerships, with Additional Expected this Year



Partnering Strategy	Current Partnerships
<p>Selective focus on high-value collaborations with near-term milestone value</p> <ul style="list-style-type: none"> • Late-stage clinical programs and/or commercialized assets • Programs with significant commercial potential • High patient quality-of-life impact with availability of self-injectable formulation • Emphasis on long-term value creation (royalties, milestone payments) if collaboration successful <p>Selective focus on pharma partners having significant strategic value to Comera</p> <ul style="list-style-type: none"> • Broad mAb asset portfolio amenable to SQ formulation with SQore • Potential interest in licensing and acquiring Comera's internal assets at downstream stages of development 	<p>Partnership #1</p> <ul style="list-style-type: none"> • Leading US biotechnology company • Three high-priority assets in development • Option to license after further technical evaluation complete <p>Partnership #2</p> <ul style="list-style-type: none"> • Top 10 global pharma company • Drug commercialized globally, currently the largest biologic drug by revenue to Company (top two overall) • Option to license after further technical evaluation complete

21

Proprietary Pipeline Strategy



Optimal Product Profile	<p>SQ formulations of widely used IV biologics</p> <ul style="list-style-type: none">• Opportunity size validated by existing market• Reduced efficacy and safety development risk with known molecular entity <p>Products with high patient quality of life impact</p> <ul style="list-style-type: none">• Chronically-administered therapies• Patients affected by disruption to work and school due to IV infusion visits
Comera Advantage	<p>Select assets where SQ^{ore} value can be leveraged</p> <ul style="list-style-type: none">• High concentration protein solutions requiring viscosity reduction• Stability challenges with viscosity reduction, addressable with SQ^{ore}
Development Goal	<p>Achieve risk reduction and value creation in early milestones</p> <ul style="list-style-type: none">• Consider asset out-licensing at key value inflection milestones (IND, Phase 1)• Preserve option to continue full development to launch

CLS-001: Addressing Unmet Need in Large Market



First program focuses on formulating a SQ version of a widely-marketed, successful IV biologic therapy targeting Inflammatory Bowel Disease (IBD)

Program	SQ formulation of marketed IV mAb
Therapeutic Area	IBD <i>Ulcerative colitis and Crohn's disease</i>
Development Status	Formulation development
Key Milestone	IND filing: Q1 2024
Competition	No SQ in US
Peak Sales Potential	\$250M-\$500M base case



Source: <https://www.grandviewresearch.com/industry-analysis/inflammatory-bowel-disease-ibd-treatment-market>; <https://www.marketwatch.com/press-release/inflammatory-bowel-disease-ibd-treatment-market-analysis-share-trends-size-forecast-from-2020-2030-2021-11-01?testla=y>; <https://www.yahoo.com/news/global-inflammatory-bowel-disease-treatment-103800897.html>; <https://qualketrresearch.com/reports-detail/inflammatory-bowel-disease-treatment-market>; Al-Horani et. al., Nat Rev Drug Disc (21);2022; Peak sales potential reflects maximum estimated sales in a 12-month period following approval.

CLS-002: Targeting Large Addressable Market with a First-in-Class SQ Formulation



Second program targets a highly growing space within immuno-oncology

Program	SQ formulation of marketed I-O mAb
Therapeutic Area	Oncology
Development Status	Formulation development
Key Milestone	IND filing: Q3 2024
Competition	No SQ available
Peak Sales Potential	\$500M-\$800M base case




Source: <https://www.biospace.com/article/immuno-oncology-therapy-market-a-paradigm-shift-from-traditional-chemotherapies-to-immunotherapies-is-propelling-the-overall-market-growth/>, <https://www.businesswire.com/news/home/20221022005402/en/Immuno-Oncology-Drugs-Global-Market-Report-2021-ResearchAndMarkets.com>, <https://www.mckinsey.com/industries/life-sciences/our-insights/delivering-innovation-2020-oncology-market-outlook>, <https://www.marketwatch.com/preas-release/immuno-oncology-market-size-share-key-players-growth-analysis-and-forecast-2028-2021-12-06>, <https://www.futurewiserresearch.com/healthcare-market-research/Immuno-Oncology-Market/10681>. Peak sales potential reflects maximum estimated sales in a 12-month period following approval.

CLS-003 and Other Emerging Pipeline Programs



We intend to announce CLS-003 in late Q1 2022 after finalization of our internal assessment; other pipeline assets in earlier stages of diligence and will be named by the end of 2022



Score™ Platform Commands Strong IP Portfolio



6 U.S. Patents

Viscosity Reducer Family
9,605,051 9,867,881
10,478,498

Stabilizer Family
10,016,513 10,279,048
10,610,600

5 International Patents

Viscosity Reducer Family

Canada	2,951,716
Japan	6674901
Japan	6983266
China	ZL2015800398




>35 Patents Pending
U.S. & International



SQore™ Well-Positioned vs. Other Approaches



Large market opportunity accommodates multiple players



Summary Transaction Overview



Overview¹	<ul style="list-style-type: none"> Implied initial equity value of approximately \$258.4 million translating into an enterprise value of approximately \$151.3 million
Ownership¹	<ul style="list-style-type: none"> All existing Comera investors are rolling 100% of their equity into the pro forma company
Earn-Out	<ul style="list-style-type: none"> 3.15 million shares issuable to Comera's existing stockholders if the pro forma stock price is at or above \$12.50 for 20 out of 30 consecutive trading days within 2 years post-closing
Transaction Rationale	<ul style="list-style-type: none"> Provides Comera with access to public markets, which will help facilitate the development of new or improved subcutaneous formulations of essential biologic medicines through additional growth capital and partnerships Attractive entry point / valuation for investors within biologics market with significant upside potential
Use of Proceeds	<ul style="list-style-type: none"> To execute on and complete new pharmaceutical partnerships and advance internal pipeline Working capital and general corporate purposes

1. Pro forma diluted basis at \$10.00 per share, assumes no redemptions and excludes impact of unvested stock-based compensation and unvested shares pursuant to the new, to-be-established equity incentive plan, earn-out shares and warrants

28




Detailed Transaction Overview

Pro Forma Valuation^{1,2}

(\$M, except per share data)

Pro Forma Shares Outstanding ²	25.8
(x) Illustrative Share Price	\$10.00
Pro Forma Equity Value²	\$258.4
(-) Pro Forma Net Cash ³	\$107.1
Pro Forma Enterprise Value²	\$151.3

Pro Forma Share Ownership^{1,2,4}



Illustrative Sources & Uses

Sources (\$M)

OTR Cash in Trust ¹	\$107.1
Comera Equity Rollover	\$126.0
Existing Comera Cash	\$7.5
OTR Founder Shares	\$26.1
Total Sources	\$266.7

Uses (\$M)


Comera Equity Rollover	\$126.0
Cash to Balance Sheet ¹	\$107.1
OTR Founder Shares	\$26.1
Transaction Cash Fees, Expenses & Deferred UW Fees	\$7.5
Total Uses	\$266.7

1. Assumes no redemptions by OTR public stockholders
 2. Pro forma diluted basis at \$10.00 per share, assumes no redemptions and excludes impact of unvested stock-based compensation and unvested shares pursuant to the new, to-be-established equity incentive plan, earn-out shares and warrants
 3. Includes existing cash of ~\$6.5M from Comera as of December 31, 2021 plus an additional ~\$1.0M from Comera employee options exercised
 4. Includes shares issued to Maxim Group LLC pursuant to a sell-side advisory fee



Compelling Valuation and Attractive Entry Point

- Proprietary platform enables potential for significant share price appreciation
- Indicative valuation range can be determined by comparing Comera to related biologics companies in the market at different stages of development
- As Comera continues to execute on its business plan, it should have ability to trade similarly to more developed biologics & novel formulation companies that tend to trade at higher valuations



Accelerated Growth as a Public Company



Market opportunity sufficiently large to accommodate multiple players

1	Proprietary Platform	→	Studied technology with significant IP protection
2	Established & Future Partnerships	→	Revenue-generating programs
3	Innovative Pipeline	→	De-risked product development
4	Experienced Management Team	→	Over 100+ years combined operating experience
5	Diversified Business Model	→	Multiple sources of revenue potential supported by core technology
6	Clear Market Opportunity	→	Addressing high unmet needs

Investment Highlights



**Proprietary Excipient
Technology Platform**

Significant Opportunity

**Multiple Pharmaceutical
Partnerships**

**Proprietary Product
Pipeline**

**Expertise and Intellectual
Property**

**Compelling Valuation and
Attractive Entry Point**

32

Thank you!

Investor Contact

John Woolford
ICR Westwicke
John.Woolford@westwicke.com

OTR Contact

Melanie Gounardes
Prosek Partners
Mgounardes@prosek.com

Comera Press Contact

Sean Leous
ICR Westwicke
Sean.Leous@westwicke.com

12 Gill Street, Suite 4650
Woburn, MA 01801, USA
comeralifesciences.com

